Valuation Update With 7 Day Price Move • Jun 02
Investor sentiment deteriorates as stock falls 15% After last week's 15% share price decline to ₩42,650, the stock trades at a forward P/E ratio of 15x. Average forward P/E is 9x in the Medical Equipment industry in South Korea. Total returns to shareholders of 56% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at ₩68,511 per share. Buy Or Sell Opportunity • Apr 30
Now 21% undervalued after recent price drop Over the last 90 days, the stock has fallen 25% to ₩55,600. The fair value is estimated to be ₩70,178, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 30% over the last 3 years. Earnings per share has grown by 15%. For the next 3 years, revenue is forecast to grow by 23% per annum. Earnings are also forecast to grow by 24% per annum over the same time period. Reported Earnings • Mar 27
Full year 2025 earnings released: EPS: ₩2,017 (vs ₩1,522 in FY 2024) Full year 2025 results: EPS: ₩2,017 (up from ₩1,522 in FY 2024). Revenue: ₩336.8b (up 39% from FY 2024). Net income: ₩131.9b (up 35% from FY 2024). Profit margin: 39% (down from 40% in FY 2024). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 24% p.a. on average during the next 3 years, compared to a 31% growth forecast for the Medical Equipment industry in South Korea. Over the last 3 years on average, earnings per share has increased by 15% per year but the company’s share price has increased by 35% per year, which means it is tracking significantly ahead of earnings growth. Duyuru • Mar 26
Cartessa Aesthetics and Classys Introduce Quadessy, A Faster, Safer and More Versatile Microneedling Radiofrequency Platform Cartessa Aesthetics is partnering with Classys Inc., to introduce QUADESSY, the next evolution of radiofrequency microneedling (RFMN), to the United States market. QUADESSY represents the latest innovation from Classys designed to address challenges and limitation in the RFMN category. QUADESSY introduces HYBRID RFMN which integrates both minimally invasive and non-invasive radiofrequency technologies. Through its proprietary Hybrid Thermal Coagulation™ approach, the system sequentially delivers RF energy across multiple layers of the skin, stimulating both superficial and deeper dermal remodeling in a single pass. This controlled thermal delivery optimizes treatment efficacy while improving patient comfort. The multi-depth design also cuts treatment time by over 50%. Treatments that once took 45 minutes to complete, now take as little as 15 minutes without impacting the amount of energy delivered to the skin. Lastly, Quadessy features multiple safety advancements including the ability to automatically measures skin impedance and adjust RF output, ensuring precise and consistent energy delivery with every pulse. The QUADESSY system features three specialized handpieces and multiple treatment tips, enabling practitioners to tailor treatments across different anatomical areas and indications. As demand for minimally invasive procedures continues to grow globally, industry leaders believe technologies that improve treatment efficiency, safety, and clinical predictability will define this next phase of growth in the RFMN category. With QUADESSY, Cartessa and Classys aim to equip providers with a platform capable of meeting both patient expectations and the evolving business needs of modern aesthetic practices. Duyuru • Mar 21
CLASSYS Inc. announces Annual dividend, payable on April 21, 2026 CLASSYS Inc. announced Annual dividend of KRW 1000.0000 per share payable on April 21, 2026, ex-date on December 29, 2025 and record date on December 31, 2025. Duyuru • Mar 17
CLASSYS Inc., Annual General Meeting, Mar 31, 2026 CLASSYS Inc., Annual General Meeting, Mar 31, 2026, at 10:00 Tokyo Standard Time. Location: conference room, 208, teheran-ro, gangnam-gu, seoul South Korea Valuation Update With 7 Day Price Move • Feb 26
Investor sentiment deteriorates as stock falls 16% After last week's 16% share price decline to ₩58,900, the stock trades at a forward P/E ratio of 21x. Average forward P/E is 13x in the Medical Equipment industry in South Korea. Total returns to shareholders of 198% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at ₩79,814 per share. Buy Or Sell Opportunity • Feb 25
Now 25% undervalued Over the last 90 days, the stock has risen 15% to ₩59,900. The fair value is estimated to be ₩80,026, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 30% over the last 3 years. Earnings per share has grown by 15%. Revenue is forecast to grow by 75% in 2 years. Earnings are forecast to grow by 81% in the next 2 years. Buy Or Sell Opportunity • Feb 05
Now 23% undervalued Over the last 90 days, the stock has risen 48% to ₩69,100. The fair value is estimated to be ₩89,816, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 30% over the last 3 years. Earnings per share has grown by 16%. Revenue is forecast to grow by 70% in 2 years. Earnings are forecast to grow by 85% in the next 2 years. Valuation Update With 7 Day Price Move • Jan 28
Investor sentiment improves as stock rises 16% After last week's 16% share price gain to ₩67,900, the stock trades at a forward P/E ratio of 26x. Average forward P/E is 11x in the Medical Equipment industry in South Korea. Total returns to shareholders of 275% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at ₩88,063 per share. Upcoming Dividend • Dec 22
Upcoming dividend of ₩257 per share Eligible shareholders must have bought the stock before 29 December 2025. Payment date: 21 April 2026. Payout ratio is a comfortable 14% and this is well supported by cash flows. Trailing yield: 0.4%. Lower than top quartile of South Korean dividend payers (3.6%). Lower than average of industry peers (1.1%). Valuation Update With 7 Day Price Move • Nov 12
Investor sentiment improves as stock rises 15% After last week's 15% share price gain to ₩54,400, the stock trades at a forward P/E ratio of 23x. Average forward P/E is 14x in the Medical Equipment industry in South Korea. Total returns to shareholders of 182% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at ₩89,251 per share. Declared Dividend • Nov 08
Dividend of ₩257 announced Dividend of ₩257 is the same as last year. Ex-date: 29th December 2025 Payment date: 21st April 2026 Dividend yield will be 0.6%, which is lower than the industry average of 1.8%. Sustainability & Growth Dividend is well covered by both earnings (16% earnings payout ratio) and cash flows (19% cash payout ratio). The dividend has increased by an average of 62% per year over the past 6 years and payments have been stable during that time. EPS is expected to grow by 86% over the next 3 years, which should provide support to the dividend and adequate earnings cover. Duyuru • Nov 07
CLASSYS Inc. announces Annual dividend, payable on April 21, 2026 CLASSYS Inc. announced Annual dividend of KRW 257.0000 per share payable on April 21, 2026, ex-date on December 29, 2025 and record date on December 31, 2025. Duyuru • May 13
CLASSYS Inc. to Report Q1, 2025 Results on May 14, 2025 CLASSYS Inc. announced that they will report Q1, 2025 results on May 14, 2025 Valuation Update With 7 Day Price Move • Apr 16
Investor sentiment improves as stock rises 18% After last week's 18% share price gain to ₩62,700, the stock trades at a forward P/E ratio of 29x. Average forward P/E is 10x in the Medical Equipment industry in South Korea. Total returns to shareholders of 195% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at ₩93,697 per share. Reported Earnings • Mar 26
Full year 2024 earnings released: EPS: ₩1,517 (vs ₩1,155 in FY 2023) Full year 2024 results: EPS: ₩1,517 (up from ₩1,155 in FY 2023). Revenue: ₩242.9b (up 35% from FY 2023). Net income: ₩97.9b (up 32% from FY 2023). Profit margin: 40% (in line with FY 2023). Revenue is forecast to grow 22% p.a. on average during the next 3 years, compared to a 22% growth forecast for the Medical Equipment industry in South Korea. Over the last 3 years on average, earnings per share has increased by 23% per year but the company’s share price has increased by 39% per year, which means it is tracking significantly ahead of earnings growth. Duyuru • Mar 15
CLASSYS Inc., Annual General Meeting, Mar 31, 2025 CLASSYS Inc., Annual General Meeting, Mar 31, 2025, at 10:00 Tokyo Standard Time. Location: conference room, 208, teheran-ro, gangnam-gu, seoul South Korea New Risk • Mar 04
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 9.8% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. This is currently the only risk that has been identified for the company. Valuation Update With 7 Day Price Move • Feb 27
Investor sentiment improves as stock rises 24% After last week's 24% share price gain to ₩69,100, the stock trades at a forward P/E ratio of 35x. Average forward P/E is 12x in the Medical Equipment industry in South Korea. Total returns to shareholders of 284% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at ₩91,640 per share. Buy Or Sell Opportunity • Feb 03
Now 20% undervalued Over the last 90 days, the stock has risen 4.1% to ₩53,200. The fair value is estimated to be ₩66,614, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 27% over the last 3 years. Earnings per share has grown by 24%. Revenue is forecast to grow by 73% in 2 years. Earnings are forecast to grow by 86% in the next 2 years. Upcoming Dividend • Dec 20
Upcoming dividend of ₩200 per share Eligible shareholders must have bought the stock before 27 December 2024. Payment date: 15 April 2025. Payout ratio is a comfortable 15% and this is well supported by cash flows. Trailing yield: 0.4%. Lower than top quartile of South Korean dividend payers (3.9%). Lower than average of industry peers (1.4%). Duyuru • Dec 10
CLASSYS Inc. (KOSDAQ:A214150) announces an Equity Buyback for KRW 25,000 million worth of its shares. CLASSYS Inc. (KOSDAQ:A214150) announces a share repurchase program. Under the program, the company will repurchase up to KRW 25,000 million worth of its shares pursuant to a contract with Samsung Securities. The purpose of the program is to improve shareholder value and to stabilize stock price. The program will expire on June 10, 2025. As of December 9, 2024, the company had 0 shares in treasury within scope available for dividend and had 3,747 shares in treasury through other repurchase.
On same day the company announced that the plan will expire on June 30, 2025. New Risk • Nov 14
New minor risk - Shareholder dilution The company's shareholders have been diluted in the past year. Increase in shares outstanding: 2.2% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. This is currently the only risk that has been identified for the company. Buy Or Sell Opportunity • Nov 11
Now 21% undervalued Over the last 90 days, the stock has risen 1.3% to ₩47,250. The fair value is estimated to be ₩60,060, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 27% over the last 3 years. Earnings per share has grown by 27%. Revenue is forecast to grow by 67% in 2 years. Earnings are forecast to grow by 62% in the next 2 years. Major Estimate Revision • Nov 09
Consensus EPS estimates fall by 11%, revenue upgraded The consensus outlook for fiscal year 2024 has been updated. 2024 revenue forecast increased from ₩235.7m to ₩242.6m. EPS estimate fell from ₩1,630 to ₩1,449 per share. Net income forecast to grow 26% next year vs 40% growth forecast for Medical Equipment industry in South Korea. Consensus price target broadly unchanged at ₩63,857. Share price was steady at ₩48,500 over the past week. Duyuru • Nov 01
CLASSYS Inc. to Report Q3, 2024 Results on Nov 07, 2024 CLASSYS Inc. announced that they will report Q3, 2024 results on Nov 07, 2024 Valuation Update With 7 Day Price Move • Oct 24
Investor sentiment deteriorates as stock falls 17% After last week's 17% share price decline to ₩51,000, the stock trades at a forward P/E ratio of 28x. Average forward P/E is 10x in the Medical Equipment industry in South Korea. Total returns to shareholders of 128% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at ₩64,608 per share. Buy Or Sell Opportunity • Oct 24
Now 21% undervalued Over the last 90 days, the stock has risen 6.5% to ₩51,000. The fair value is estimated to be ₩64,608, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 27% over the last 3 years. Earnings per share has grown by 27%. Revenue is forecast to grow by 60% in 2 years. Earnings are forecast to grow by 61% in the next 2 years. Buy Or Sell Opportunity • Aug 28
Now 22% undervalued Over the last 90 days, the stock has risen 5.6% to ₩50,700. The fair value is estimated to be ₩64,650, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 27% over the last 3 years. Earnings per share has grown by 27%. Revenue is forecast to grow by 58% in 2 years. Earnings are forecast to grow by 61% in the next 2 years. Valuation Update With 7 Day Price Move • Jun 13
Investor sentiment improves as stock rises 16% After last week's 16% share price gain to ₩54,300, the stock trades at a forward P/E ratio of 32x. Average forward P/E is 12x in the Medical Equipment industry in South Korea. Total returns to shareholders of 198% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at ₩26,299 per share. Price Target Changed • May 10
Price target increased by 8.0% to ₩48,500 Up from ₩44,889, the current price target is an average from 10 analysts. New target price is approximately in line with last closing price of ₩48,500. Stock is up 103% over the past year. The company is forecast to post earnings per share of ₩1,610 for next year compared to ₩1,155 last year. Valuation Update With 7 Day Price Move • May 09
Investor sentiment improves as stock rises 29% After last week's 29% share price gain to ₩48,500, the stock trades at a forward P/E ratio of 31x. Average forward P/E is 13x in the Medical Equipment industry in South Korea. Total returns to shareholders of 253% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at ₩43,350 per share. Duyuru • May 03
CLASSYS Inc. to Report Q1, 2024 Results on May 08, 2024 CLASSYS Inc. announced that they will report Q1, 2024 results on May 08, 2024 Reported Earnings • Mar 24
Full year 2023 earnings released: EPS: ₩1,155 (vs ₩1,165 in FY 2022) Full year 2023 results: EPS: ₩1,155 (down from ₩1,165 in FY 2022). Revenue: ₩180.1b (up 27% from FY 2022). Net income: ₩74.2b (down 1.5% from FY 2022). Profit margin: 41% (down from 53% in FY 2022). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 19% p.a. on average during the next 3 years, compared to a 18% growth forecast for the Medical Equipment industry in South Korea. Over the last 3 years on average, earnings per share has increased by 31% per year but the company’s share price has increased by 37% per year, which means it is tracking significantly ahead of earnings growth. Buy Or Sell Opportunity • Mar 19
Now 23% overvalued Over the last 90 days, the stock has fallen 4.9% to ₩36,250. The fair value is estimated to be ₩29,418, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 28% over the last 3 years. Earnings per share has grown by 34%. For the next 3 years, revenue is forecast to grow by 19% per annum. Earnings are also forecast to grow by 15% per annum over the same time period. Duyuru • Mar 16
CLASSYS Inc., Annual General Meeting, Mar 28, 2024 CLASSYS Inc., Annual General Meeting, Mar 28, 2024, at 10:00 Korea Standard Time. Location: 20F Conference Room, 208 Teheran-ro, (CLASSYS, Yeoksam-dong), Gangnam-gu, Seoul South Korea Agenda: To consider Audit report; to consider Operating report; to consider Report on the operating status of the internal accounting control system; to consider Approval of the 9th consolidated and non-consolidated financial statements (cash dividend of KRW 200 per share); to consider Appointment of directors; to consider Appointment of outside director becoming a member of the audit committee Kwon Hyuk-jin; to consider Appointment of members of the audit committee; to consider Approval of the directors’ remuneration limit (same as last year, KRW 3 billion); and to consider Approval of stock option granted by the board of directors’ resolution. Buy Or Sell Opportunity • Feb 05
Now 22% undervalued after recent price drop Over the last 90 days, the stock has fallen 17% to ₩28,400. The fair value is estimated to be ₩36,587, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 28% over the last 3 years. Earnings per share has grown by 34%. For the next 3 years, revenue is forecast to grow by 18% per annum. Earnings are also forecast to grow by 15% per annum over the same time period. Upcoming Dividend • Dec 20
Upcoming dividend of ₩116 per share at 0.3% yield Eligible shareholders must have bought the stock before 27 December 2023. Payment date: 17 April 2024. Payout ratio is a comfortable 8.4% and this is well supported by cash flows. Trailing yield: 0.3%. Lower than top quartile of South Korean dividend payers (3.5%). Lower than average of industry peers (1.6%). New Risk • Nov 23
New major risk - Earnings quality The company has a high level of non-cash earnings. Accrual ratio: 22% This is considered a major risk. Non-cash earnings can arise from many different things. However, if a company consistently has a high level of non-cash earnings, it may be a sign that they are recognizing revenue from customers before the full value of the sales are received as cash or they are not depreciating the value of their assets appropriately. These are practices that inflate earnings, while not providing a similar increase to cash flows. Companies in some select industries naturally have a high level of non-cash earnings and it is not a major concern. However, in the worst case scenario it can be an early sign of performance manipulation by management. This is currently the only risk that has been identified for the company. Valuation Update With 7 Day Price Move • Oct 10
Investor sentiment deteriorates as stock falls 16% After last week's 16% share price decline to ₩31,700, the stock trades at a forward P/E ratio of 24x. Average forward P/E is 12x in the Medical Equipment industry in South Korea. Total returns to shareholders of 111% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at ₩42,532 per share. Valuation Update With 7 Day Price Move • Oct 10
Investor sentiment deteriorates as stock falls 16% After last week's 16% share price decline to ₩31,700, the stock trades at a forward P/E ratio of 24x. Average forward P/E is 12x in the Medical Equipment industry in South Korea. Total returns to shareholders of 111% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at ₩42,532 per share. Price Target Changed • Aug 15
Price target increased by 11% to ₩38,500 Up from ₩34,714, the current price target is an average from 8 analysts. New target price is 10% above last closing price of ₩34,850. Stock is up 126% over the past year. The company is forecast to post earnings per share of ₩1,201 for next year compared to ₩1,165 last year. Valuation Update With 7 Day Price Move • Aug 10
Investor sentiment improves as stock rises 20% After last week's 20% share price gain to ₩34,900, the stock trades at a forward P/E ratio of 28x. Average forward P/E is 15x in the Medical Equipment industry in South Korea. Total returns to shareholders of 146% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at ₩55,353 per share. Price Target Changed • Jul 05
Price target increased by 8.3% to ₩34,667 Up from ₩32,000, the current price target is an average from 6 analysts. New target price is 6.3% above last closing price of ₩32,600. Stock is up 126% over the past year. The company is forecast to post earnings per share of ₩1,166 for next year compared to ₩1,165 last year. Price Target Changed • Jun 19
Price target increased by 10% to ₩32,000 Up from ₩29,000, the current price target is an average from 6 analysts. New target price is approximately in line with last closing price of ₩32,050. Stock is up 112% over the past year. The company is forecast to post earnings per share of ₩1,168 for next year compared to ₩1,165 last year. Valuation Update With 7 Day Price Move • Jun 14
Investor sentiment improves as stock rises 21% After last week's 21% share price gain to ₩32,900, the stock trades at a forward P/E ratio of 27x. Average forward P/E is 13x in the Medical Equipment industry in South Korea. Total returns to shareholders of 111% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at ₩30,314 per share. Reported Earnings • May 21
First quarter 2023 earnings released: EPS: ₩292 (vs ₩198 in 1Q 2022) First quarter 2023 results: EPS: ₩292 (up from ₩198 in 1Q 2022). Revenue: ₩39.0b (up 10% from 1Q 2022). Net income: ₩18.8b (up 47% from 1Q 2022). Profit margin: 48% (up from 36% in 1Q 2022). Revenue is forecast to grow 17% p.a. on average during the next 3 years, compared to a 9.9% growth forecast for the Medical Equipment industry in South Korea. Over the last 3 years on average, earnings per share has increased by 26% per year but the company’s share price has only increased by 17% per year, which means it is significantly lagging earnings growth. Price Target Changed • May 16
Price target increased by 9.5% to ₩27,600 Up from ₩25,200, the current price target is an average from 5 analysts. New target price is 12% above last closing price of ₩24,700. Stock is up 42% over the past year. The company is forecast to post earnings per share of ₩1,168 for next year compared to ₩1,165 last year. Valuation Update With 7 Day Price Move • Mar 30
Investor sentiment improves as stock rises 15% After last week's 15% share price gain to ₩21,800, the stock trades at a forward P/E ratio of 21x. Average forward P/E is 12x in the Medical Equipment industry in South Korea. Total returns to shareholders of 141% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at ₩32,089 per share. Price Target Changed • Feb 01
Price target decreased by 15% to ₩23,000 Down from ₩27,000, the current price target is an average from 5 analysts. New target price is 25% above last closing price of ₩18,390. Stock is up 20% over the past year. The company is forecast to post earnings per share of ₩933 for next year compared to ₩677 last year. Upcoming Dividend • Dec 21
Upcoming dividend of ₩66.00 per share Eligible shareholders must have bought the stock before 28 December 2022. Payment date: 17 April 2023. Payout ratio is a comfortable 7.8% but the company is not cash flow positive. Trailing yield: 0.3%. Lower than top quartile of South Korean dividend payers (3.3%). Lower than average of industry peers (1.8%). Major Estimate Revision • Nov 16
Consensus EPS estimates increase by 13% The consensus outlook for earnings per share (EPS) in 2022 has improved. 2022 revenue forecast increased from ₩136.8m to ₩138.9m. EPS estimate increased from ₩812 to ₩919 per share. Net income forecast to grow 31% next year vs 23% growth forecast for Medical Equipment industry in South Korea. Consensus price target broadly unchanged at ₩26,571. Share price rose 15% to ₩19,600 over the past week. Board Change • Nov 16
Less than half of directors are independent There are 8 new directors who have joined the board in the last 3 years. Of these new board members, 3 were independent directors. The company's board is composed of: 8 new directors. No experienced directors. No highly experienced directors. 3 independent directors (5 non-independent directors). Independent Outside Director Jin Kwon Hyuk is the most experienced director on the board, commencing their role in 2022. Independent Outside Director Jun Hong Park was the last independent director to join the board, commencing their role in 2022. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity. Lack of experienced directors. Major Estimate Revision • Nov 11
Consensus EPS estimates increase by 12% The consensus outlook for earnings per share (EPS) in 2022 has improved. 2022 revenue forecast increased from ₩136.8m to ₩141.8m. EPS estimate increased from ₩812 to ₩905 per share. Net income forecast to grow 25% next year vs 22% growth forecast for Medical Equipment industry in South Korea. Consensus price target broadly unchanged at ₩27,167. Share price rose 20% to ₩18,350 over the past week. Valuation Update With 7 Day Price Move • Nov 10
Investor sentiment improved over the past week After last week's 20% share price gain to ₩18,350, the stock trades at a forward P/E ratio of 20x. Average forward P/E is 10x in the Medical Equipment industry in South Korea. Total returns to shareholders of 14% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at ₩22,344 per share. Duyuru • Sep 16
CLASSYS Inc. (KOSDAQ:A214150) announces an Equity Buyback for KRW 20,000 million worth of its shares. CLASSYS Inc. (KOSDAQ:A214150) announces a share repurchase program. Under the program, the company will repurchase up to KRW 20,000 million worth of its shares pursuant to a contract with Samsung Securities. The purpose of the program is to improve shareholder value and to stabilize stock price. The program will expire on March 22, 2023. As of September 14, 2022, the company had 0 shares in treasury within scope available for dividend and had 0 shares in treasury through other repurchase. Buying Opportunity • Apr 20
Now 20% undervalued Over the last 90 days, the stock is up 32%. The fair value is estimated to be ₩27,214, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 18% over the last 3 years. Earnings per share has grown by 25%. For the next 3 years, revenue is forecast to grow by 23% per annum. Earnings is also forecast to grow by 20% per annum over the same time period. Duyuru • Apr 07
Bain Capital, LP agreed to acquire a 60.84% stake in CLASSYS Inc. (KOSDAQ : A214150) from Jung Sung-jae, his wife Lee Yeon-joo and their two children. Bain Capital, LP agreed to acquire a 60.84% stake in CLASSYS Inc. (KOSDAQ : A214150) from Jung Sung-jae, his wife Lee Yeon-joo and their two children for approximately KRW 670 billion on January 27, 2022. Bain Capital paid KRW 17,000 per share for 39.41 million shares, representing a 60.84% stake in CLASSYS. Before the transaction, Jung and his three family members held a combined 73.77% stake. Jung and Lee will remain friendly shareholders for the next few years with a combined 12.93% stake. The transaction will be funded from KRW 354.9 billion through the fund and Samsung Securities and KEB Hana Bank arranged the remaining KRW 315 billion financing for the purchase.
Bain Capital, LP completed the acquisition of a 60.84% stake in CLASSYS Inc. (KOSDAQ : A214150) from Jung Sung-jae, his wife Lee Yeon-joo and their two children for approximately KRW 670 billion on April 6, 2022. Valuation Update With 7 Day Price Move • Feb 18
Investor sentiment improved over the past week After last week's 19% share price gain to ₩19,000, the stock trades at a forward P/E ratio of 22x. Average forward P/E is 13x in the Medical Equipment industry in South Korea. Total returns to shareholders of 219% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at ₩35,473 per share. Upcoming Dividend • Dec 22
Upcoming dividend of ₩60.00 per share Eligible shareholders must have bought the stock before 29 December 2021. Payment date: 11 April 2022. Payout ratio is a comfortable 8.2% and this is well supported by cash flows. Trailing yield: 0.3%. Lower than top quartile of South Korean dividend payers (2.4%). Lower than average of industry peers (0.7%). Valuation Update With 7 Day Price Move • Dec 07
Investor sentiment improved over the past week After last week's 15% share price gain to ₩20,250, the stock trades at a forward P/E ratio of 23x. Average forward P/E is 12x in the Medical Equipment industry in South Korea. Total returns to shareholders of 369% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at ₩32,298 per share. Reported Earnings • Nov 18
Third quarter 2021 earnings released: EPS ₩194 (vs ₩136 in 3Q 2020) The company reported a strong third quarter result with improved earnings, revenues and profit margins. Third quarter 2021 results: Revenue: ₩24.5b (up 25% from 3Q 2020). Net income: ₩12.5b (up 42% from 3Q 2020). Profit margin: 51% (up from 45% in 3Q 2020). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 39% per year but the company’s share price has increased by 60% per year, which means it is tracking significantly ahead of earnings growth. Price Target Changed • Aug 18
Price target increased to ₩26,333 Up from ₩24,250, the current price target is an average from 8 analysts. New target price is approximately in line with last closing price of ₩25,300. Stock is up 81% over the past year. Valuation Update With 7 Day Price Move • Jun 19
Investor sentiment improved over the past week After last week's 16% share price gain to ₩19,350, the stock trades at a forward P/E ratio of 26x. Average forward P/E is 17x in the Medical Equipment industry in South Korea. Total returns to shareholders of 377% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at ₩26,405 per share. Reported Earnings • May 17
First quarter 2021 earnings released: EPS ₩148 (vs ₩176 in 1Q 2020) The company reported a poor first quarter result with weaker earnings and profit margins, although revenues were flat. First quarter 2021 results: Revenue: ₩21.3b (flat on 1Q 2020). Net income: ₩9.56b (down 16% from 1Q 2020). Profit margin: 45% (down from 53% in 1Q 2020). Over the last 3 years on average, earnings per share has increased by 64% per year but the company’s share price has only increased by 37% per year, which means it is significantly lagging earnings growth. Reported Earnings • Mar 21
Full year 2020 earnings released: EPS ₩590 (vs ₩534 in FY 2019) The company reported a decent full year result with improved earnings and profit margins, although revenues were weaker. Full year 2020 results: Revenue: ₩76.5b (down 5.8% from FY 2019). Net income: ₩38.2b (up 14% from FY 2019). Profit margin: 50% (up from 41% in FY 2019). The increase in margin was driven by lower expenses. Over the last 3 years on average, earnings per share has increased by 78% per year but the company’s share price has only increased by 30% per year, which means it is significantly lagging earnings growth. Is New 90 Day High Low • Feb 22
New 90-day low: ₩14,500 The company is down 4.0% from its price of ₩15,150 on 24 November 2020. The South Korean market is up 18% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Medical Equipment industry, which is up 6.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is ₩23,724 per share. Duyuru • Feb 04
CLASSYS Inc., Annual General Meeting, Mar 31, 2021 CLASSYS Inc., Annual General Meeting, Mar 31, 2021, at 09:00 Korea Standard Time. Is New 90 Day High Low • Jan 26
New 90-day high: ₩17,500 The company is up 17% from its price of ₩14,950 on 28 October 2020. The South Korean market is up 36% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Medical Equipment industry, which is up 15% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is ₩23,887 per share. Upcoming Dividend • Dec 22
Upcoming Dividend of ₩46.00 Per Share Will be paid on the 10th of April to those who are registered shareholders by the 29th of December. The trailing yield of 0.3% is below the top quartile of South Korean dividend payers (2.6%), and is lower than industry peers (0.7%). Price Target Changed • Nov 16
Price target raised to ₩19,667 Up from ₩17,500, the current price target is an average from 5 analysts. The new target price is 24% above the current share price of ₩15,850. As of last close, the stock is down 10% over the past year. Is New 90 Day High Low • Nov 12
New 90-day high: ₩16,650 The company is up 14% from its price of ₩14,600 on 14 August 2020. The South Korean market is up 2.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Medical Equipment industry, which is down 2.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is ₩17,657 per share.